Dr. George M. Goldfarb, MD

Dr. Goldfarb practices at St. Vincent's Medical Center in Bridgeport, Connecticut, part of Hartford HealthCare.

Dr. Goldfarb's NPI, 1194750471, was assigned on July 12, 2006. Dr. Goldfarb holds Connecticut license 028645.

Dr. Goldfarb's primary practice is St. Vincent's Medical Center, at 2800 Main St, Bridgeport, CT 06606 in Fairfield County. The practice phone is (203) 576-5551.

Dr. Goldfarb's primary practice is St. Vincent's Medical Center in Bridgeport, Connecticut, part of Hartford HealthCare. Dr. Goldfarb is also affiliated with Bridgeport Hospital. The medical group on file is Hartford HealthCare Medical Group. Dmand AI also links Dr. Goldfarb to 1 more hospital, 5 skilled nursing facilities, 4 home health agencies, 3 group practices and clinics, 3 hospices and 2 medical groups, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Goldfarb practices, 18 sites in all. Vendor and product names are available with a free account.

Internal medicine is Dr. Goldfarb's primary specialty in the NPI Registry, under taxonomy code 207R00000X. Dr. Goldfarb is licensed in Connecticut.

CMS data shows 2,300 Medicare services from Dr. Goldfarb across 16 procedure codes in 2024, for 785 Medicare patients. Medicare paid $181,418 for them.

CMS counts 785 Medicare patients who saw Dr. Goldfarb in 2024. The largest group is 85 and over, with 292 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 33% are also on Medicaid. Their average risk score is 1.97, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Goldfarb's median patient age at 71, with 46% women.

In 2024, Dr. Goldfarb wrote 30,131 Medicare Part D claims for 1,156 patients. 88% of them were for generic drugs. CMS names the drug for 29,152 of them, across 220 drugs with 11 or more claims each, at $1,271,239 in total drug cost. In 2023, CMS named 18,626 claims across 199 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 94 out of 100 for Dr. Goldfarb for performance year 2024, reported through an alternative payment model (APM). Dr. Goldfarb accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Goldfarb as offering telehealth.

CMS Open Payments shows 46 general payments to Dr. Goldfarb from 6 drug and device companies from 2016 to 2025. Food and beverage make up the largest share, 100% of the total. Abbvie Inc. paid the most, $345.